Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

GU14-188

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

Status: Open to Accrual

This is a two-part trial with a one-arm phase Ib portion followed by a two-arm phase II portion. The study treatment is stratified into two cohorts based on cisplatin eligibility.

  • Condition: Urothelial Carcinoma
  • Intervention:
    • Drug: Pembrolizumab
    • Drug: Gemcitabine
    • Drug: Cisplatin
    • Procedure: Consolidative Surgery
  • Phase: Phase 1b/2

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

  • C.J. Hoimes, R. Abouassaly, J.N. Saltzman, M.T. Fleming, J.H. Hoffman-Censits, T. Byrd, C. Eitman, M. Snyder-Willis, J. O’Neill, L. Wood, R. Elliott, M.M. Cooney. HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC). Accepted as a trials in progress poster session at the ASCO Annual Meeting, June 3-7, 2016, Chicago IL. J Clin Oncol 34, 2016 (suppl; abstr TPS4578). See abstract.

Project Manager: Michael Nunley, mnunley@hoosiercancer.org; (317) 634-5842, ext. 17.